In this post hoc analysis of the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, we evaluated the effect of 1-year treatment with the SGLT2 inhibitor canagliflozin on serum iron, TIBC, TSAT and ferritin levels in patients with type 2 diabetes and CKD. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.